ABSTRACT
Background Tuberculosis (TB) disease is the leading cause of mortality among people living with the Human immunodeficiency virus (PLHIV). Interferon-gamma release assays (IGRAs) are approved for TB infection ascertainment. However, current IGRA data on the prevalence of TB infection in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking. We estimated the prevalence and determinants of TB infection among PLHIV within a high TB and HIV burden context.
Methods This cross-sectional study included data from adult PLHIV age ≥ 18 years in whom QuantiFERON-TB Gold Plus (QFT-Plus) assay, an IGRA, was performed. TB infection was defined as a positive or indeterminate QFT-Plus test. Participants with TB and those who had previously used TPT were excluded. Regression analysis was performed to identify independent predictors of TB infection.
Results Of 121 PLHIV with QFT-Plus test results, females were 74.4% (90/121), and the mean age was 38.4 (standard deviation [SD] 10.8) years. Overall, 47.9% (58/121) were classified as TB infection (QFT-Plus test positive and indeterminate results were 39.7% [48/121] and 8.3% [10/121], respectively), with mean ages of 38.7 (SD 10.30) vs 38.2 (SD 11.3) years, respectively (p=0.602). Being obese/overweight (body mass index ≥25; p=0.013, adjusted odds ratio (aOR) 2.90, 95% confidence interval [CI] 1.25–6.74) and ART usage for >3 years (p=0.013, aOR 3.99, 95% CI 1.55– 10.28) were independently associated with TB infection.
Conclusion There was a high TB infection prevalence among PLHIV. A longer period of ART and obesity were independently associated with TB infection. The relationship between obesity/overweight and TB infection may be related to ART and immune reconstitution and requires further investigation. Given the known benefit of test-directed TPT among PLHIV never exposed to TPT, its clinical and cost implications for low and middle-income countries should be explored further.
What is already known on this topic Among people living with HIV (PLHIV), the risk of progression to tuberculosis (TB) disease is higher with confirmed and untreated TB infection. Data on the prevalence of TB infection in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking in Africa.
What this study adds This study provides evidence that the prevalence of TB infection remains high even in the context of near-universal ART and widespread TPT. ART use and obesity/overweight may be associated with TB infection.
How this study might affect research, practice or policy This study should prompt larger studies to explore predictors of TB infection. TPT should remain as part of care for PLHIV on ART. A broader understanding of the clinical and cost implications of test-directed TPT for PLHIV in low and middle-income countries may better inform policy towards its recommendation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Consortium for Advanced Research Training in Africa (CARTA), the Royal Society of Tropical Medicine and Hygiene (RSTMH), and the World Bank through the Materials, Products, and Nano Technology Africa Center of Excellence (MAPRONANO ACE) project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Kenyatta National Hospital and University of Nairobi Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Further justification of concepts and multivariate analysis using only factors that met a significance level of less than 0.1%. Addition of patient flow diagram as figure 1
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- ART
- antiretroviral therapy
- CD4
- cluster of differentiation 4
- CI
- confidence interval
- HIV
- human immunodeficiency virus
- HBC
- high burden country
- IGRA
- interferon-gamma release assay
- LTBI
- latent tuberculosis infection
- PLHIV
- people living with human immunodeficiency virus
- SD
- standard deviation
- TB
- tuberculosis
- TPT
- tuberculosis preventive therapy
- WHO
- World Health Organization
